Compare NRIM & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | ZVRA |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.8M | 741.9M |
| IPO Year | 2002 | 2015 |
| Metric | NRIM | ZVRA |
|---|---|---|
| Price | $26.57 | $13.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 125.1K | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | ★ 0.61 | 0.60 |
| Revenue | ★ $255,581,000.00 | $106,470,000.00 |
| Revenue This Year | $4.98 | $37.27 |
| Revenue Next Year | $7.40 | $53.42 |
| P/E Ratio | $42.77 | ★ $21.67 |
| Revenue Growth | 30.43 | ★ 350.91 |
| 52 Week Low | $19.60 | $7.16 |
| 52 Week High | $99.18 | $14.27 |
| Indicator | NRIM | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 62.38 |
| Support Level | $26.26 | $8.26 |
| Resistance Level | $28.10 | $14.27 |
| Average True Range (ATR) | 0.81 | 0.77 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 90.18 | 69.99 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.